Form 4: Atara Biotherapeutics Director William K. Heiden Acquires 150,000 Shares of Common Stock

Director William K. Heiden acquired 150,000 shares of Atara Biotherapeutics common stock on March 31, 2024.

Summary

• On March 31, 2024, William K. Heiden, a director of Atara Biotherapeutics, acquired 150,000 shares of common stock.
• The acquisition was made at a price of $0 per share.
• Following the transaction, Heiden directly owns 359,000 shares of Atara Biotherapeutics common stock.
• The acquired securities are restricted stock units that will vest on the date of the Issuer's annual meeting of stockholders for the calendar year 2025, subject to the Reporting Person's continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's stock acquisition, which can be seen as a mildly positive signal but doesn't provide strong evidence for a bullish or bearish outlook.

Positives

• A director's acquisition of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The restricted stock units will vest on the date of the Issuer's annual meeting of stockholders for the calendar year 2025, subject to the Reporting Person's continuous service.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The acquisition of shares by a director could positively influence shareholder sentiment.

Key Dates